More specifically, in pancreatic cancer, KRAS mutations result in a constitutively active protein which upregulates the PI3K/Akt cascade; the suppression of which is not feasible due to loss of PTEN in earlier stages of the disease (reviewed in [116]). This evidence concerns the gene PIK3CA and familial pancreatic carcinoma.